| 2025 |
Wright, L., Wignall, A., Subramaniam, S., Schultz, H. B., Joyce, P., & Prestidge, C. A. (2025). Enhanced oral absorption and biodistribution to submandibular salivary glands of D-limonene in Sprague Dawley rats via a liquid-lipid formulation approach. International Journal of Pharmaceutics, 670(125179), 125179.
DOI Scopus1 WoS1 Europe PMC1 |
| 2025 |
Hosseini-Kharat, M., Wignall, A., Mekonnen, Z. A., Ung, B. S. -Y., Chereda, B., Bremmell, K. E., . . . Prestidge, C. A. (2025). Microfluidic Optimization of PEI-Lipid Hybrid Nanoparticles for Efficient DNA Delivery and Transgene Expression. Pharmaceutics, 17(4), 454.
DOI Scopus1 WoS1 |
| 2025 |
Subramaniam, S., Donnellan, L., Wignall, A., Woodcock, J., Coolen, C., Pitson, S., . . . Joyce, P. (2025). Polymeric-lipid nanoparticles that leverage cationic helper lipids and the protein corona for lung-targeted delivery of a novel anti-cancer drug. Journal of Controlled Release, 388(Pt 1), 15 pages.
DOI |
| 2025 |
Taheri, A., Almasri, R., Wignall, A., Feltrin, F., Bremmell, K. E., Joyce, P., & Prestidge, C. A. (2025). Enteric coating enhances the Biopharmaceutical performance of a silica-lipid formulation of Abiraterone Acetate. Pharmaceutics, 17(10, article no. 1289), 1-12.
DOI |
| 2025 |
Arafat, M., Wignall, A., Brewer, K., Song, Y., Albrecht, H., Prestidge, C. A., . . . Blencowe, A. (2025). Comparison of polymer-coated, drug-eluting self-expandable metal stents for the potential treatment of gastrointestinal cancers. Rsc Pharmaceutics, 2(3), 611-623.
DOI |
| 2024 |
Taheri, A., Almasri, R., Wignall, A., Schultz, H. B., Elz, A. S., Ariaee, A., . . . Prestidge, C. A. (2024). Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: addressing solubility and food effect challenges. Drug Delivery and Translational Research, online(11), 3770-3782.
DOI WoS2 Europe PMC1 |
| 2024 |
Meola, T. R., Kamath, S., Elz, A. S., Prestidge, C. A., Wignall, A., & Joyce, P. (2024). Contrasting the pharmacokinetic performance and gut microbiota effects of an amorphous solid dispersion and lipid nanoemulsion for a poorly water-soluble anti-psychotic. European Journal of Pharmaceutics and Biopharmaceutics, 203, 10 pages.
DOI Scopus2 WoS2 Europe PMC1 |
| 2024 |
Kamath, S., Hunter, A., Collins, K., Wignall, A., & Joyce, P. (2024). The atypical antipsychotics lurasidone and olanzapine exert contrasting effects on the gut microbiome and metabolic function of rats. British Journal of Pharmacology, 181(22), 4531-4545.
DOI WoS10 Europe PMC10 |
| 2024 |
Meola, T. R., Elz, A., Wignall, A., Paxton, K., Hunter, A., Ariaee, A., . . . Joyce, P. (2024). Inulin-Lipid Core–Shell Microcapsules Target the Gut Microbiota and Mimic the Pharmaceutical Food Effect for Improved Oral Antipsychotic Delivery. Advanced Functional Materials, 34(40), 12 pages.
DOI Scopus14 WoS14 |
| 2024 |
Ariaee, A., Wardill, H. R., Wignall, A., Prestidge, C. A., & Joyce, P. (2024). The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats. Foods, 13(7), 1039.
DOI Scopus11 WoS10 Europe PMC9 |
| 2024 |
Ariaee, A., Wardill, H. R., Wignall, A., Elz, A. S., Wright, L., Prestidge, C., & Joyce, P. (2024). Therapeutic Potential of Inulin-Coated MCT Microcapsules in Modulating the Gut Microbiome for Effective Treatment of Diet-Induced Obesity. Advanced Therapeutics, 8(3), 13 pages.
DOI |
| 2024 |
Brewer, K., Wignall, A., Bazeed, A., Gundsambuu, B., Kohlhagen, J., Yan, J., . . . Blencowe, A. (2024). Customizable and Open-Source 3D Printed Inserts for Controlled Release and Cell Culture Experiments. ACS Applied Polymer Materials, 6(19), 11813-11827.
DOI |
| 2024 |
Ariaee, A., Wardill, H. R., Wignall, A., Prestidge, C. A., & Joyce, P. (2024). Correction: Ariaee et al. The Degree of Inulin Polymerization Is Important for Short-Term Amelioration of High-Fat Diet (HFD)-Induced Metabolic Dysfunction and Gut Microbiota Dysbiosis in Rats. Foods 2024, 13, 1039. Foods, 13(24), 4030.
DOI |
| 2024 |
Cross, C., Davies, M., Bateman, E., Crame, E., Joyce, P., Wignall, A., . . . Bowen, J. (2024). Fibre-rich diet attenuates chemotherapy-related neuroinflammation in mice. Brain, Behavior, and Immunity, 115, 13-25.
DOI Scopus12 WoS12 Europe PMC7 |
| 2023 |
Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., . . . Joyce, P. (2023). Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. International Journal of Pharmaceutics, 648(123614), 123614-1-123614-10.
DOI Scopus31 WoS27 Europe PMC19 |
| 2023 |
Wright, L., Wignall, A., Jõemetsa, S., Joyce, P., & Prestidge, C. A. (2023). A membrane-free microfluidic approach to mucus permeation for efficient differentiation of mucoadhesive and mucopermeating nanoparticulate systems. Drug Delivery and Translational Research, 13(4), 1088-1101.
DOI Scopus11 WoS12 Europe PMC10 |
| 2023 |
Awad, M., Kopecki, Z., Barnes, T. J., Wignall, A., Joyce, P., Thomas, N., & Prestidge, C. A. (2023). Lipid Liquid Crystal Nanoparticles: Promising Photosensitizer Carriers for the Treatment of Infected Cutaneous Wounds. Pharmaceutics, 15(2), 1-18.
DOI Scopus6 WoS5 Europe PMC3 |
| 2023 |
Jambhrunkar, M., Maghrebi, S., Doddakyathanahalli, D., Wignall, A., Prestidge, C. A., & Bremmell, K. E. (2023). Mesoporous organosilica nanoparticles to fight intracellular staphylococcal aureus infections in macrophages. Pharmaceutics, 15(4, article no. 1037), 1-12.
DOI WoS4 Europe PMC1 |
| 2023 |
Jia, Z., Wignall, A., Delon, L., Guo, Z., Prestidge, C., & Thierry, B. (2023). An ex vivo model enables systematic investigation of the intestinal absorption and transcytosis of oral particulate nanocarriers. ACS Biomaterials Science and Engineering, 9(6), 2857-2867.
DOI Scopus3 WoS5 Europe PMC4 |
| 2023 |
Subramaniam, S., Joyce, P., Donnellan, L., Young, C., Wignall, A., Hoffmann, P., & Prestidge, C. A. (2023). Protein adsorption determines pulmonary cell uptake of lipid-based nanoparticles. Journal of Colloid and Interface Science, 641, 36-47.
DOI Scopus32 WoS31 Europe PMC23 |
| 2022 |
Thorn, C. R., Wignall, A., Kopecki, Z., Kral, A., Prestidge, C. A., & Thomas, N. (2022). Liquid Crystal Nanoparticles Enhance Tobramycin Efficacy in a Murine Model of Pseudomonas aeruginosa Biofilm Wound Infection. ACS Infectious Diseases, 8(4), 841-854.
DOI Scopus15 WoS15 Europe PMC13 |
| 2022 |
Thorn, C. R., Kopecki, Z., Wignall, A., Kral, A., Prestidge, C. A., & Thomas, N. (2022). Liquid crystal nanoparticle platform for increased efficacy of cationic antimicrobials against biofilm infections. Nanomedicine Nanotechnology Biology and Medicine, 42(102536), 12 pages.
DOI Scopus11 WoS8 Europe PMC8 |
| 2022 |
Secombe, K. R., Ball, I. A., Wignall, A. D., Bateman, E., Keefe, D. M., & Bowen, J. M. (2022). Antibiotic treatment targeting gram negative bacteria prevents neratinib-induced diarrhea in rats. Neoplasia, 30(article no. 100806), 100806-1-100806-10.
DOI Scopus13 WoS13 Europe PMC13 |
| 2022 |
Tam, J. S. Y., Crame, E. E., Elz, A. S., Coller, J. K., Wignall, A., Prestidge, C. A., & Bowen, J. M. (2022). Effects of a novel toll-like receptor 4 antagonist IAXO-102 in a murine model of chemotherapy-induced gastrointestinal toxicity. Cancer Chemotherapy and Pharmacology, 90(3), 267-278.
DOI Scopus5 WoS4 Europe PMC5 |
| 2022 |
Joyce, P., Wignall, A., Peressin, K., Wright, L., Williams, D. B., & Prestidge, C. A. (2022). Chitosan nanoparticles facilitate improved intestinal permeation and oral pharmacokinetics of the mast cell stabiliser cromoglycate. International Journal of Pharmaceutics, 612(121382), 121382.
DOI Scopus15 WoS16 Europe PMC9 |
| 2021 |
Secombe, K. R., Ball, I. A., Shirren, J., Wignall, A. D., Keefe, D. M., & Bowen, J. M. (2021). Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.. Breast Cancer, 28(1), 99-109.
DOI Scopus12 WoS9 Europe PMC10 |
| 2021 |
Arafat, M., Fouladian, P., Wignall, A., Song, Y., Parikh, A., Albrecht, H., . . . Blencowe, A. (2021). Development and in vitro evaluation of 5-fluorouracil-eluting stents for the treatment of colorectal cancer and cancer-related obstruction. Pharmaceutics, 13(1), 1-22.
DOI Scopus23 WoS20 Europe PMC11 |
| 2021 |
Meola, T. R., Joyce, P., Wignall, A., Bremmell, K. E., & Prestidge, C. A. (2021). Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone. International Journal of Pharmaceutics, 608(121098), 10 pages.
DOI Scopus11 WoS11 Europe PMC7 |
| 2020 |
Joyce, P., Dening, T. J., Meola, T. R., Wignall, A., Ulmefors, H., Kovalainen, M., & Prestidge, C. A. (2020). Contrasting Anti-obesity Effects of Smectite Clays and Mesoporous Silica in Sprague-Dawley Rats. ACS Applied Bio Materials, 3(11), 7779-7788.
DOI Scopus13 WoS13 Europe PMC10 |
| 2020 |
Joyce, P., Ulmefors, H., Maghrebi, S., Subramaniam, S., Wignall, A., Jõemetsa, S., . . . Prestige, C. A. (2020). Enhancing the cellular uptake and antibacterial activity of rifampicin through encapsulation in mesoporous silica nanoparticles. Nanomaterials, 10(4), 1-16.
DOI WoS31 Europe PMC25 |
| 2020 |
Mayo, B., Secombe, K., Wignall, A., Bateman, E., Thorpe, D., Pietra, C., . . . Bowen, J. (2020). The GLP-2 Analogue Elsiglutide Reduces Diarrhoea Caused by the Tyrosine Kinase Inhibitor Lapatinib in Rats. Cancer Chemotherapy and Pharmacology, 85(4), 793-803.
DOI Scopus26 WoS21 Europe PMC22 |
| 2019 |
Tam, S. Y. J., Coller, J. K., Wignall, A., Gibson, R. J., Khatri, A., Barbé, C., & Bowen, J. M. (2019). Intestinal accumulation of silica particles in a rat model of dextran sulfate sodium-induced colitis.. Annals of gastroenterology, 32(6), 584-592.
DOI Scopus7 WoS6 Europe PMC6 |
| 2019 |
Secombe, K., Ball, I., Shirren, J., Wignall, A., Finnie, J., Keefe, D., . . . Bowen, J. (2019). Targeting neratinib-induced diarrhea with budesonide and colesevelam in a rat model. Cancer Chemotherapy and Pharmacology, 83(3), 531-543.
DOI Scopus18 WoS12 Europe PMC14 |
| 2018 |
Gibson, R. J., Van Sebille, Y. Z. A., Wardill, H. R., Wignall, A., Shirren, J., Ball, I. A., . . . Bowen, J. M. (2018). Selective MMP inhibition, using AZD3342, to reduce gastrointestinal toxicity and enhance chemoefficacy in a rat model. Chemotherapy, 63(5), 284-292.
DOI Scopus5 WoS5 Europe PMC2 |
| 2018 |
Stansborough, R. L., Bateman, E. H., Al-Dasooqi, N., Bowen, J. M., Wignall, A., Keefe, D. M., . . . Gibson, R. J. (2018). Vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), angiostatin, and endostatin are increased in radiotherapy-induced gastrointestinal toxicity. International Journal of Radiation Biology, 94(7), 645-655.
DOI Scopus8 WoS6 Europe PMC6 |
| 2017 |
Coller, J. K., Bowen, J. M., Ball, I. A., Wardill, H. R., Van Sebille, Y. Z. A., Stansborough, R. L., . . . Gibson, R. J. (2017). Potential safety concerns of TLR4 antagonism with irinotecan: a preclinical observational report. Cancer Chemotherapy and Pharmacology, 79(2), 431-434.
DOI Scopus9 WoS8 Europe PMC8 |
| 2016 |
Bateman, E., Weaver, E., Klein, G., Wignall, A., Wozniak, B., Plews, E., . . . Keefe, D. (2016). Serum-derived bovine immunoglobulin/protein isolate in the alleviation of chemotherapy-induced mucositis. Supportive Care in Cancer, 24(1), 377-385.
DOI Scopus10 WoS11 Europe PMC11 |
| 2014 |
Bowen, J., Mayo, B., Plews, E., Bateman, E., Wignall, A., Stringer, A., . . . Keefe, D. (2014). Determining the mechanisms of lapatinib-induced diarrhoea using a rat model. Cancer Chemotherapy and Pharmacology, 74(3), 617-627.
DOI Scopus27 WoS22 Europe PMC19 |
| 2013 |
Bateman, E., Bowen, J., Stringer, A., Mayo, B., Plews, E., Wignall, A., . . . Keefe, D. (2013). Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal model. Nutrients, 5(10), 3948-3963.
DOI Scopus9 WoS10 Europe PMC9 |
